[go: up one dir, main page]

WO2013011179A3 - Recombinant vectors based on the modified vaccinia ankara (mva) virus, with deletion in the c6l gene, as vaccines against hiv/aids and other diseases - Google Patents

Recombinant vectors based on the modified vaccinia ankara (mva) virus, with deletion in the c6l gene, as vaccines against hiv/aids and other diseases Download PDF

Info

Publication number
WO2013011179A3
WO2013011179A3 PCT/ES2012/070521 ES2012070521W WO2013011179A3 WO 2013011179 A3 WO2013011179 A3 WO 2013011179A3 ES 2012070521 W ES2012070521 W ES 2012070521W WO 2013011179 A3 WO2013011179 A3 WO 2013011179A3
Authority
WO
WIPO (PCT)
Prior art keywords
mva
virus
aids
diseases
gene
Prior art date
Application number
PCT/ES2012/070521
Other languages
Spanish (es)
French (fr)
Other versions
WO2013011179A2 (en
Inventor
Juan Francisco GARCÍA ARRIAZA
Carmen Elena Gómez Rodríguez
Mariano ESTEBAN RODRÍGUEZ
Original Assignee
Consejo Superior De Investigaciones Científicas (Csic)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior De Investigaciones Científicas (Csic) filed Critical Consejo Superior De Investigaciones Científicas (Csic)
Publication of WO2013011179A2 publication Critical patent/WO2013011179A2/en
Publication of WO2013011179A3 publication Critical patent/WO2013011179A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention falls within the fields of molecular biology and biotechnology. It specifically relates to recombinant viruses based on the modified vaccinia ankara (MVA) virus, that express the antigens gp120 and Gag-Pol-Nef of the human immunodeficiency virus (VIH-1) of sub-type B (MVA-B), and wherein the C6L vaccinia gene has been deleted, said recombinant viruses having been designed to be used as vaccines against HIV/AIDS and other diseases.
PCT/ES2012/070521 2011-07-19 2012-07-11 Recombinant vectors based on the modified vaccinia ankara (mva) virus, with deletion in the c6l gene, as vaccines against hiv/aids and other diseases WO2013011179A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201131230A ES2401904B1 (en) 2011-07-19 2011-07-19 RECOMBINANT VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE C6L GEN, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES.
ESP201131230 2011-07-19

Publications (2)

Publication Number Publication Date
WO2013011179A2 WO2013011179A2 (en) 2013-01-24
WO2013011179A3 true WO2013011179A3 (en) 2013-03-14

Family

ID=47558548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2012/070521 WO2013011179A2 (en) 2011-07-19 2012-07-11 Recombinant vectors based on the modified vaccinia ankara (mva) virus, with deletion in the c6l gene, as vaccines against hiv/aids and other diseases

Country Status (2)

Country Link
ES (1) ES2401904B1 (en)
WO (1) WO2013011179A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086980A1 (en) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Vaccine composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085932A2 (en) * 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2010127115A1 (en) * 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085932A2 (en) * 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2010127115A1 (en) * 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GARCIA-ARRIAZA, J ET AL.: "A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses", PLOS ONE, vol. 6, no. 8, August 2011 (2011-08-01) *
GARCIA-ARRIAZA, J ET AL.: "Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions", PLOS ONE, vol. 5, no. 8, August 2010 (2010-08-01) *
GONZALEZ, J. M ET AL.: "A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history", VIROLOGY JOURNAL, vol. 7, no. 1, March 2010 (2010-03-01) *
GUERRA, S ET AL.: "Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS", JOURNAL OF VIROLOGY, vol. 84, no. 16, August 2010 (2010-08-01), pages 8141 - 8152 *
UNTERHOLZNER, L ET AL.: "Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7.", PLOS PATHOGENS, vol. 7, no. 9, September 2011 (2011-09-01) *

Also Published As

Publication number Publication date
ES2401904B1 (en) 2014-04-07
WO2013011179A2 (en) 2013-01-24
ES2401904A2 (en) 2013-04-25
ES2401904R1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
WO2016109792A8 (en) Novel multivalent nanoparticle-based vaccines
HK1214509A1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
EP4043031A3 (en) Zika viral antigen constructs
WO2016020856A3 (en) Immunological reagents binding to pd-1
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
NZ702145A (en) Bluetongue virus recombinant vaccines and uses thereof
BR112013012555A2 (en) Immunogenic peptides for use in the prevention and / or treatment of infectious diseases, autoimmune diseases, immune responses to allopaths, allergic diseases, tumors, graft rejection, and immune responses against viral vectors used for gene therapy or gene vaccination.
WO2010019262A3 (en) Polyvalent vaccine
PH12013502322A1 (en) Hendra and nipah virus g glycoprotein immunogenic compositions
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2014052378A3 (en) Subunit immersion vaccines for fish
CA2860388C (en) Parainfluenza virus 5 based vaccines
WO2012106231A3 (en) Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
WO2015052543A3 (en) Malaria vaccination
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
MX346475B (en) Monomeric and multimeric immunogenic peptides.
EP3971298A3 (en) Compositions and methods for inducing an enhanced immune response using poxvirus vectors
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
EP4494651A3 (en) Modified viruses
WO2011119716A3 (en) Flavivirus host range mutations and uses thereof
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
WO2012116253A3 (en) Recombinant mumps virus vaccine
WO2015123592A3 (en) Recombinant rna particles and methods of use
WO2012003320A3 (en) Flavivirus host-range mutations and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12815519

Country of ref document: EP

Kind code of ref document: A2